혈장 분획 시장 : 시장 규모, 점유율, 성장률, 산업 분석 - 유형별, 용도별, 지역별 인사이트, 예측(2026-2034년)

Growth Factors of plasma fractionation Market

The global plasma fractionation market is a vital component of the biopharmaceutical industry, enabling the separation of human plasma into therapeutic proteins such as immunoglobulins, albumin, coagulation factors, and protease inhibitors. These plasma-derived products are essential for treating immunodeficiency disorders, bleeding disorders, metabolic diseases, neurological conditions, and critical care complications. Continuous growth in chronic and rare disease prevalence, along with expansion of plasma collection infrastructure, is strengthening market demand worldwide.

Plasma Fractionation Market Size and Market Value

According to the 2025 market report, the global plasma fractionation market size was valued at USD 40.27 billion in 2025. The market is projected to grow to USD 43.55 billion in 2026, supported by increasing plasma donation volumes, growing demand for immunoglobulin therapies, and expansion of fractionation capacity by major manufacturers. Over the long-term forecast period, the market is expected to reach a market value of USD 87.20 billion by 2034, reflecting strong demand for plasma-derived medicinal products across multiple therapeutic areas. The market is projected to grow at a CAGR of 9.10% from 2026 to 2034, driven by rising healthcare spending and increasing regulatory approvals of plasma-based biologics.

Market Drivers Supporting Growth

A major growth driver is the increasing prevalence of immunodeficiency disorders, autoimmune diseases, and rare genetic bleeding disorders such as hemophilia A, hemophilia B, and von Willebrand disease. Plasma-derived therapies remain the primary treatment option for many of these conditions, supporting consistent demand for fractionated products. Rising numbers of patients with HIV, primary immunodeficiency disorders, and chronic liver disease are also contributing to higher immunoglobulin and albumin consumption.

Government support for plasma-derived medicinal product manufacturing is further strengthening market growth. Several regulatory bodies recognize plasma therapies as essential medicines, encouraging national plasma self-sufficiency programs and investment in domestic fractionation capacity. Increasing funding for blood services, regulatory relaxation for plasma usage, and public-private partnerships are improving plasma availability and strengthening production pipelines.

Market Trends and Technology Advancements

Technological advancements in plasma fractionation are improving production efficiency, yield, and protein purity. Automation, improved chromatography systems, and optimized separation techniques are enabling manufacturers to maximize output from each liter of collected plasma. Next-generation donor collection systems are also improving donor safety and reducing plasma collection time, enhancing supply stability.

Another emerging trend is the development of biological products and biosimilars derived from plasma proteins. Manufacturers are expanding clinical research programs to explore new therapeutic indications for immunoglobulins and albumin in neurology, liver disease, and inflammatory disorders. Strategic collaborations between biopharmaceutical companies and protein technology providers are accelerating biologics development using plasma proteins as critical raw materials.

Market Restraints and Challenges

Despite strong demand, the plasma fractionation market faces challenges related to high production costs, strict regulatory compliance, and plasma supply dependency. Fractionation facilities require highly specialized equipment, validated purification processes, and strict viral inactivation protocols, which increase operational expenses. Regulatory approvals for plasma-derived products often involve lengthy clinical and manufacturing evaluations, delaying market entry.

The increasing adoption of recombinant therapies presents competitive pressure. Recombinant clotting factors and biologics offer reduced infection risk and longer half-life, leading to increased use in prophylactic treatment regimens. These alternatives are gradually reducing dependence on plasma-derived coagulation factors in certain patient groups.

Plasma supply chain stability also remains a challenge, as plasma is sourced exclusively from human donors. Any disruption in donor recruitment, logistics, or regulatory policies can directly impact manufacturing capacity and product availability.

Segmentation Analysis by Product

By product, the market includes immunoglobulins, albumin, coagulation factors, protease inhibitors, and others. The immunoglobulin segment dominated the market with a 53.76% share in 2026, driven by rising use in primary and secondary immunodeficiency disorders and autoimmune diseases. Increasing regulatory approvals for both IVIG and SCIG formulations are strengthening clinical adoption.

The albumin segment held the second-largest share, supported by growing use in liver diseases, critical care, sepsis, and hypoalbuminemia. Coagulation factors are witnessing strong growth due to the continued prevalence of bleeding disorders, particularly in emerging markets where access to recombinant alternatives remains limited. Protease inhibitors are gaining moderate traction in infectious disease and inflammatory disorder treatments.

Segmentation by Application and End User

By application, immunology and neurology accounted for the largest market share, estimated at 70.50% in 2026, driven by expanding indications for immunoglobulin therapies in autoimmune neuropathies and immune disorders. Hematology represents the second-largest segment, supported by hemophilia management programs and clotting factor demand. Critical care applications are rising due to increasing trauma cases and surgical interventions.

By end user, hospitals and clinics dominated the market with an estimated 86.67% share in 2026, supported by high inpatient use of plasma therapies and centralized treatment protocols. Clinical research laboratories are growing steadily due to expanding plasma-based drug development programs.

Regional Outlook

North America dominated the plasma fractionation market with a market size of USD 24.50 billion in 2025 and USD 26.57 billion in 2026, supported by extensive plasma collection networks, strong reimbursement systems, and high therapeutic adoption. Europe held the second-largest share in 2026, driven by increasing plasma self-sufficiency initiatives and expansion of fractionation facilities.

Asia Pacific is emerging as a high-growth region due to expanding healthcare infrastructure, rising chronic disease prevalence, and increasing domestic plasma manufacturing investments in China, Japan, and India. Latin America and the Middle East & Africa are witnessing gradual growth supported by government healthcare investments and rising demand for immunoglobulin therapies.

Competitive Landscape

The plasma fractionation market is highly consolidated, with major players including CSL Behring, Grifols, Takeda Pharmaceutical Company Limited, Octapharma, Kedrion, ADMA Biologics, Sartorius AG, and LFB. Companies are actively expanding plasma collection centers, investing in fractionation capacity, and launching new plasma-derived products. Strategic acquisitions, long-term plasma supply agreements, and facility expansions remain central to competitive strategies across global markets.

Conclusion

The global plasma fractionation market is positioned for strong and sustained expansion, supported by rising prevalence of immunodeficiency, autoimmune, and bleeding disorders, along with continuous growth in demand for immunoglobulins, albumin, and coagulation factors. With the market valued at USD 40.27 billion in 2025, projected to reach USD 43.55 billion in 2026 and further expand to USD 87.20 billion by 2034, the industry reflects robust long-term growth potential. Ongoing investments in plasma collection networks, expansion of fractionation capacity, technological advancements in purification and automation, and increasing regulatory approvals for plasma-derived therapies are strengthening market penetration across hospitals and specialty treatment centers. Although challenges such as high production costs, regulatory complexity, and competition from recombinant therapies persist, rising healthcare spending, government support for plasma self-sufficiency programs, and expanding clinical applications of plasma-derived products are expected to continue driving market momentum globally.

Segmentation By Product

• Albumin
• Immunoglobulin
  • Intravenous Immunoglobulin
  • Subcutaneous Immunoglobulin
• Coagulation Factors
  • Factor IX
  • Factor VIII
  • Prothrombin Complex Concentrates
  • Fibrinogen Concentrates
  • Others
• Protease Inhibitors
• Others

By Application

• Immunology & Neurology
• Hematology
• Critical Care
• Pulmonology
• Others

By End-user

• Hospitals & Clinics
• Clinical Research Laboratories
• Others

By Region

• North America (By Product, Application, End-user, and Country)
• U.S. (By Product)
• Canada (By Product)
• Europe (By Product, Application, End-user, and Country/Sub-Region)
• U.K. (By Product)
• Germany (By Product)
• France (By Product)
• Italy (By Product)
• Spain (By Product)
• Scandinavia (By Product)
• Rest of Europe (By Product)
• Asia Pacific (By Product, Application, End-user, and Country/Sub-Region)
• China (By Product)
• Japan (By Product)
• India (By Product)
• Australia (By Product)
• Southeast Asia (By Product)
• Rest of Asia Pacific (By Product)
• Latin America (By Product, Application, End-user, and Country/Sub-Region)
• Brazil (By Product)
• Mexico (By Product)
• Rest of Latin America (By Product)
• Middle East & Africa (By Product, Application, End-user, and Country/Sub-Region)
• GCC (By Product)
• South Africa (By Product)
• Rest of Middle East & Africa (By Product)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Plasma Fractionation Capacity, By Key Players
• 4.2. Number of Plasma Collection Centers, By Key Countries
• 4.3. Cost Breakdown of Plasma Fractionation, By Key Countries
• 4.4. Regional Distribution of Plasma Fractionation Throughput
• 4.5. Prevalence of Chronic Diseases (Key Indications), By Key Countries
• 4.6. Pricing Analysis, Plasma Fractionated Products, By Key Countries
• 4.7. Regulatory Scenario, By Key Countries
• 4.8. Overview : Plasma Collection Technologies
• 4.9. Pipeline Analysis, By Key Companies
• 4.10. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
• 4.11. Impact of COVID-19 on the Market

5. Global Plasma Fractionation Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Product
  • 5.1.1. Albumin
  • 5.1.2. Immunoglobulin
    • 5.1.2.1. Intravenous Immunoglobulin
    • 5.1.2.2. Subcutaneous Immunoglobulin
  • 5.1.3. Coagulation Factors
    • 5.1.3.1. Factor IX
    • 5.1.3.2. Factor VIII
    • 5.1.3.3. Prothrombin Complex Concentrates
    • 5.1.3.4. Fibrinogen concentrates
    • 5.1.3.5. Others
  • 5.1.4. Protease Inhibitors
  • 5.1.5. Others
• 5.2. Market Analysis, Insights and Forecast - By Application
  • 5.2.1. Immunology & Neurology
  • 5.2.2. Hematology
  • 5.2.3. Critical Care
  • 5.2.4. Pulmonology
  • 5.2.5. Others
• 5.3. Market Analysis, Insights and Forecast - By End-user
  • 5.3.1. Hospitals & Clinics
  • 5.3.2. Clinical Research Laboratories
  • 5.3.3. Others
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Plasma Fractionation Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Product
  • 6.1.1. Albumin
  • 6.1.2. Immunoglobulin
    • 6.1.2.1. Intravenous Immunoglobulin
    • 6.1.2.2. Subcutaneous Immunoglobulin
  • 6.1.3. Coagulation Factors
    • 6.1.3.1. Factor IX
    • 6.1.3.2. Factor VIII
    • 6.1.3.3. Prothrombin Complex Concentrates
    • 6.1.3.4. Fibrinogen concentrates
    • 6.1.3.5. Others
  • 6.1.4. Protease Inhibitors
  • 6.1.5. Others
• 6.2. Market Analysis, Insights and Forecast - By Application
  • 6.2.1. Immunology & Neurology
  • 6.2.2. Hematology
  • 6.2.3. Critical Care
  • 6.2.4. Pulmonology
  • 6.2.5. Others
• 6.3. Market Analysis, Insights and Forecast - By End-user
  • 6.3.1. Hospitals & Clinics
  • 6.3.2. Clinical Research Laboratories
  • 6.3.3. Others
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
    • 6.4.1.1. By Product
  • 6.4.2. Canada
    • 6.4.2.1. By Product

7. Europe Plasma Fractionation Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Product
  • 7.1.1. Albumin
  • 7.1.2. Immunoglobulin
    • 7.1.2.1. Intravenous Immunoglobulin
    • 7.1.2.2. Subcutaneous Immunoglobulin
  • 7.1.3. Coagulation Factors
    • 7.1.3.1. Factor IX
    • 7.1.3.2. Factor VIII
    • 7.1.3.3. Prothrombin Complex Concentrates
    • 7.1.3.4. Fibrinogen concentrates
    • 7.1.3.5. Others
  • 7.1.4. Protease Inhibitors
  • 7.1.5. Others
• 7.2. Market Analysis, Insights and Forecast - By Application
  • 7.2.1. Immunology & Neurology
  • 7.2.2. Hematology
  • 7.2.3. Critical Care
  • 7.2.4. Pulmonology
  • 7.2.5. Others
• 7.3. Market Analysis, Insights and Forecast - By End-user
  • 7.3.1. Hospitals & Clinics
  • 7.3.2. Clinical Research Laboratories
  • 7.3.3. Others
• 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.4.1. U.K.
    • 7.4.1.1. By Product
  • 7.4.2. Germany
    • 7.4.2.1. By Product
  • 7.4.3. France
    • 7.4.3.1. By Product
  • 7.4.4. Spain
    • 7.4.4.1. By Product
  • 7.4.5. Italy
    • 7.4.5.1. By Product
  • 7.4.6. Scandinavia
    • 7.4.6.1. By Product
  • 7.4.7. Rest of Europe
    • 7.4.7.1. By Product

8. Asia Pacific Plasma Fractionation Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Product
  • 8.1.1. Albumin
  • 8.1.2. Immunoglobulin
    • 8.1.2.1. Intravenous Immunoglobulin
    • 8.1.2.2. Subcutaneous Immunoglobulin
  • 8.1.3. Coagulation Factors
    • 8.1.3.1. Factor IX
    • 8.1.3.2. Factor VIII
    • 8.1.3.3. Prothrombin Complex Concentrates
    • 8.1.3.4. Fibrinogen concentrates
    • 8.1.3.5. Others
  • 8.1.4. Protease Inhibitors
  • 8.1.5. Others
• 8.2. Market Analysis, Insights and Forecast - By Application
  • 8.2.1. Immunology & Neurology
  • 8.2.2. Hematology
  • 8.2.3. Critical Care
  • 8.2.4. Pulmonology
  • 8.2.5. Others
• 8.3. Market Analysis, Insights and Forecast - By End-user
  • 8.3.1. Hospitals & Clinics
  • 8.3.2. Clinical Research Laboratories
  • 8.3.3. Others
• 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.4.1. Japan
    • 8.4.1.1. By Product
  • 8.4.2. China
    • 8.4.2.1. By Product
  • 8.4.3. India
    • 8.4.3.1. By Product
  • 8.4.4. Australia
    • 8.4.4.1. By Product
  • 8.4.5. Southeast Asia
    • 8.4.5.1. By Product
  • 8.4.6. Rest of Asia Pacific
    • 8.4.6.1. By Product

9. Latin America Plasma Fractionation Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Product
  • 9.1.1. Albumin
  • 9.1.2. Immunoglobulin
    • 9.1.2.1. Intravenous Immunoglobulin
    • 9.1.2.2. Subcutaneous Immunoglobulin
  • 9.1.3. Coagulation Factors
    • 9.1.3.1. Factor IX
    • 9.1.3.2. Factor VIII
    • 9.1.3.3. Prothrombin Complex Concentrates
    • 9.1.3.4. Fibrinogen concentrates
    • 9.1.3.5. Others
  • 9.1.4. Protease Inhibitors
  • 9.1.5. Others
• 9.2. Market Analysis, Insights and Forecast - By Application
  • 9.2.1. Immunology & Neurology
  • 9.2.2. Hematology
  • 9.2.3. Critical Care
  • 9.2.4. Pulmonology
  • 9.2.5. Others
• 9.3. Market Analysis, Insights and Forecast - By End-user
  • 9.3.1. Hospitals & Clinics
  • 9.3.2. Clinical Research Laboratories
  • 9.3.3. Others
• 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.4.1. Brazil
    • 9.4.1.1. By Product
  • 9.4.2. Mexico
    • 9.4.2.1. By Product
  • 9.4.3. Rest of Latin America
    • 9.4.3.1. By Product

10. Middle East & Africa Plasma Fractionation Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Product
  • 10.1.1. Albumin
  • 10.1.2. Immunoglobulin
    • 10.1.2.1. Intravenous Immunoglobulin
    • 10.1.2.2. Subcutaneous Immunoglobulin
  • 10.1.3. Coagulation Factors
    • 10.1.3.1. Factor IX
    • 10.1.3.2. Factor VIII
    • 10.1.3.3. Prothrombin Complex Concentrates
    • 10.1.3.4. Fibrinogen concentrates
    • 10.1.3.5. Others
  • 10.1.4. Protease Inhibitors
  • 10.1.5. Others
• 10.2. Market Analysis, Insights and Forecast - By Application
  • 10.2.1. Immunology & Neurology
  • 10.2.2. Hematology
  • 10.2.3. Critical Care
  • 10.2.4. Pulmonology
  • 10.2.5. Others
• 10.3. Market Analysis, Insights and Forecast - By End-user
  • 10.3.1. Hospitals & Clinics
  • 10.3.2. Clinical Research Laboratories
  • 10.3.3. Others
• 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.4.1. GCC
    • 10.4.1.1. By Product
  • 10.4.2. South Africa
    • 10.4.2.1. By Product
  • 10.4.3. Rest of Middle East & Africa
    • 10.4.3.1. By Product

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. CSL Behring (CSL)
    • 11.2.1.1. Overview
    • 11.2.1.2. Products
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Grifols, S.A
    • 11.2.2.1. Overview
    • 11.2.2.2. Products
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Takeda Pharmaceutical Company Limited
    • 11.2.3.1. Overview
    • 11.2.3.2. Products
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Kedrion S.p.A
    • 11.2.4.1. Overview
    • 11.2.4.2. Products
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Octapharma
    • 11.2.5.1. Overview
    • 11.2.5.2. Products
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. ADMA Biologics, Inc.
    • 11.2.6.1. Overview
    • 11.2.6.2. Products
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Sartorius AG
    • 11.2.7.1. Overview
    • 11.2.7.2. Products
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. LFB
    • 11.2.8.1. Overview
    • 11.2.8.2. Products
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)